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Abstract
Background—Estimates of population-based incidence for rotavirus inpatient and outpatient 
visits, as well as their associated medical costs, can provide valuable information to assess the 
potential benefits of rotavirus vaccination.
Methods—We conducted active surveillance for rotavirus gastroenteritis at 6 medical institutions 
for children younger than 5 years from July 2012 to June 2013 in Beijing Municipality and Gansu 
Province. We collected stool samples of diarrhea patients for testing rotavirus, and 
epidemiological, clinical and cost data.
Results—The proportion of rotavirus-positive for inpatient and outpatient visits from Beijing 
was 28.7% (138/481) and 19.4% (133/687); a statistically lower proportion than observed in 
Gansu among inpatient visits (45.2%, 245/542, P < 0.001) and among outpatient visits (28.8%, 
66/229, P = 0.003), respectively. The G9P[8] genotype was most prevalent in Beijing (60.6%) and 
in Gansu (77.6%). The median Vesikari scale value was 16 for rotavirus inpatients and 15 for 
nonrotavirus inpatients. Population-based estimated rates of rotavirus-related hospitalizations were 
14.4 (95% CI, 13–16) per 10,000 children, and the rate of rotavirus gastroenteritis in the outpatient 
setting was 149 (95% CI, 145–153) per 10,000 children younger than 5 years. The estimated total 
number of rotavirus-related inpatient visits were 3790 (95% CI, 2488–3827) cases and 29,101 
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(95% CI: 27,748–29,279) outpatient visits. The total cost of rotavirus infection was $1.4 million 
(95% CI, $0.9–1.4 million) for hospitalizations and $4.2 million (95% CI, $4.0–4.2 million) for 
outpatient visits per year in Beijing and Gansu.
Conclusion—Rotavirus gastroenteritis is associated with a large disease burden in Chinese 
children younger than 5 years in Beijing and Gansu. Rotavirus is the most common cause of 
severe acute gastroenteritis (AGE) in children younger than 5 years worldwide, accounting for an 
estimated 25 million clinic visits, 2 million hospitalizations and 453,000 deaths each year.1,2 In 
China, the world’s most populous nation, surveillance at sentinel hospitals showed that 
approximately 48% of AGE hospitalizations among children younger than 5 years were attributed 
to rotavirus from 2003 to 2007, and 13,387 rotavirus deaths were estimated in China in 2002 
alone.3,4 The Lanzhou lamb rotavirus vaccine, consisting of serotype G10P[12], was licensed in 
2000 but is not included in the National Expanded Program of Immunization vaccine 
recommendations for Chinese children.5 License applications for new rotavirus vaccines (Rotarix, 
produced by GlaxoSmithKline Biologicals, and RotaTeq, produced by Merck and Company) have 
been submitted for administering these vaccines to Chinese infants.
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Chinese laboratory-based and hospitalized-based surveillance capacity includes monitoring 
rotavirus test-positive rates and strain genotypes since 19983,6,7 among inpatients younger 
than 5 years with diarrhea in selected sentinel hospitals. However, active, population-based 
surveillance to understand the epidemiology and estimate the burden of rotavirus 
gastroenteritis among Chinese children has only recently been established by the Chinese 
Center for Disease Control and Prevention in China’s Beijing Municipality and Gansu 
Province. This surveillance provides the information on the incidence of rotavirus inpatient 
and outpatient visits, as well as their associated medical costs, thereby providing valuable 
information to assess the potential benefits of rotavirus vaccination in China.
MATERIALS AND METHODS
Surveillance Sites and Population
Active, prospective, population-based surveillance was conducted from July 2012 to June 
2013 in Beijing Municipality and Gansu Province (Fig. 1). Beijing Municipality holds one 
of the largest metropolitan populations in the world and is among the most 
socioeconomically developed cities throughout China. Gansu Province is located in the 
north-west region of China and has a lower socioeconomic status. Surveillance was 
conducted in the 3 districts (Xicheng district, Chao yang district and Tong Zhou district) of 
Beijing Municipality, and in Gansu Province’s Liang Zhou district which includes Wuwei 
city and Lanzhou city. Six medical institutions participated in this surveillance. Four 
hospitals were selected in Beijing Municipality: Beijing Children’s Hospital, Peking 
University First Hospital, Capital Pediatric Research Institute, and Tong Zhou District 
Women and Children’s Medical Center. Two medical institutions in Gansu Province 
participated: Lanzhou University Hospital and Liangzhou District Hospital of Wuwei city. 
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On the basis of national infectious disease reporting demographic statistics data in 2012,8 
the total population of children younger than 5 years in these surveillance areas was 
399,484.
Case Definition and Enrollment of Patients
Children 14 days to 59 months old were considered eligible for enrollment if they presented 
to the surveillance hospitals with symptoms of AGE, defined as ≥3 loose stools and /or ≥1 
episode of vomiting within 24 hours. Confirmed rotavirus case-patients were those whose 
stools had rotavirus detected by enzyme-linked immunoassay (EIA). AGE patients were 
divided into mild cases (Vesikari scale score <11), moderate cases (Vesikari scale score of 
11–14) and severe cases (Vesikari scale scores ≥15).9 Hospitalized AGE case-patients were 
those admitted as inpatients for a stay lasting ≥24 hours or having intravenous rehydration 
therapy for >2 days in the outpatient clinic.
The enrolled patients with AGE symptom both in inpatient and outpatient sites have 
informed consent from a parent or guardian. Inpatient surveillance enrollment of all eligible 
inpatients occurred systematically through the study period. Outpatient surveillance 
enrollment occurred for all eligible AGE subjects visiting the medical institution 2 days per 
week in Beijing Municipality and on 3 days per week in Gansu Province.
Data Collection and Analysis
A standardized questionnaire to consenting parents/guardians that collected demographic, 
medical history, socioeconomic data, clinical data, rotavirus vaccination status and 
medically related economic costs. The direct medical care costs of hospitalizations was 
examined from a hospital administrative database, and direct nonmedical costs (eg, travel 
costs, nonprescription medications) and indirect costs (eg, lost work days for parents) were 
collected during follow-up interviews. The cost of lost work days was estimated using cost 
per person/work day of Beijing and Gansu in the Chinese Statistics Yearbook, 2012.8 All 
enrolled patients follow-up visits finished within approximately 14 days after discharge.
We attempted to collect a whole stool sample from each case-patient within 7 days of AGE 
symptom onset. Each specimen was immediately stored at −20°C, and tested for rotavirus 
antigen by EIA using the group A rotavirus detection kit (IDEIA Rotavirus, Dako). 
Rotavirus EIA-positive specimens were analyzed for rotavirus serotype and genotype 
detection by multiplex, reverse transcription-polymerase chain reaction methods and 
nucleotide sequencing according to the guideline for rotavirus laboratory detection provided 
by Chinese Center for Disease Control and Prevention.
Statistical analyses were conducted by using SPSS 16.0 software and Microsoft Excel. 
Comparisons were made by using Pearson’s χ2 test and Kruskal–Wallis test. Population-
based hospitalization and outpatient visit rates were calculated as the weighted number of 
children enrolled with AGE with laboratory-confirmed rotavirus infections among inpatient 
and outpatient subjects, divided by the childhood population8 multiplied by 10,000. Weights 
were calculated to account for the proportion of patients who were eligible and enrolled in 
the study, and the proportion of eligible children who resided within the catchment area for 
the medical institutions conducting surveillance. The surveillance capture rates of eligible 
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children was estimated to be 98%, according to an enteric disease clinic database in Beijing 
Municipality, and 60% of inpatient visits and 50% of outpatient visits based on infectious 
diarrhea disease reporting surveillance areas in Gansu Province according to Gansu 
provincial health resource information. The costs attributable to rotavirus in Beijing 
Municipality and Gansu Province were estimated using the population-based hospitalization 
and outpatient visit rates, multiplied by the total number of resident children younger than 5 
years in each surveillance area.
RESULTS
In total, 28,153 AGE case-patients (including 1176 inpatient and 26,977 outpatient visits) 
were identified as eligible patients in Beijing Municipality and Gansu Province. A total of 
1939 AGE patients were enrolled; 1023 and 916 from the inpatient and outpatient clinical 
settings, respectively. From Beijing Municipality, we collected stool samples from 481 
(94%) of 511 eligible hospitalized patients and from a sample of 687 (3.2%) of 21,513 
eligible outpatient visits. From Gansu Province, we collected stool samples from 542 (82%) 
of 665 eligible hospitalized AGE patients and from 229 (4.2%) of 5464 eligible AGE 
outpatient visits in Gansu Province. Rotavirus vaccination was self-reported and just 48 
(2.5%) of the 1939 AGE patients were reported to have received any rotavirus vaccination. 
No deaths were observed among our enrolled AGE patients.
Epidemiologic Characteristics of Rotavirus-related AGE
Overall, 30.0% (582/1939) of children in this surveillance assessment were confirmed 
rotavirus-positive. Among the 1023 inpatient children, 383 (37.4%) were rotavirus-positive, 
and of 916 outpatient patients, 199 (21.7%) were rotavirus-positive (P < 0.001) (Table 1). 
The proportion of rotavirus-positive patients from inpatient settings and outpatient settings 
from Beijing Municipality was 28.7% (138/481) and 19.4% (133/687); a statistically lower 
proportion than observed in Gansu Province (45.2%, 245/542, P = 0.001) among inpatient 
visits and 28.8% (66/229, P = 0.003) among outpatient visits, respectively. Rotavirus 
positivity in Gansu Province was higher than Beijing Municipality across each strata 
(gender, race, urban/rural residence, insurance and vaccination) (Table 1).
Infants in Gansu Province had higher proportions of rotavirus positivity compared with 
Beijing Municipality (P < 0.001). In Gansu Province, rotavirus was detected in high 
proportions even among the youngest infants, including 0–2 month olds (42.9%, n = 21 of 
49), 3–5 month olds (30.2%, n = 45 of 149) and 6–11 month olds (44.6%, n = 172 of 386).
Dual rotavirus seasonal peaks were observed in Beijing Municipality from October to 
December and in April, and dual seasonal peaks were also observed in Gansu Province from 
October to December and from March to May (Fig. 2A, B).
Rotavirus Strain Characterization
A sample of 298 rotavirus positive specimens were genotyped by reverse transcription-
polymerase chain reaction (231 from Beijing Municipality and 67 from Gansu Province) and 
sequenced to determine their G and P genotypes (Fig. 3A, B). Overall, G9P[8] rotavirus 
infections were most prevalent both in Beijing Municipality (60.6%) and in Gansu Province 
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(77.6%), followed by G3P[8] (8.2%) and G2P[4] (7.8%) in Beijing Municipality, and 
G2P[4] (9.0%) and G1P[8] (4.5%) genotypes in Gansu Province, respectively.
Clinical Severity
Of 582 rotavirus AGE patients, 63.6% (n = 370 of 582) were classified as severe cases, 
having Vesikari scale scores ≥15. Among the 1357 rotavirus-negative patients, only 40.4% 
were classified as severe infections according to this scale (Table 2). The difference between 
these Vesikari scale values for rotavirus AGE (median scores, hospitalized = 16, outpatient 
= 14) compared with values for nonrotavirus AGE (median scores, hospitalized = 15, 
outpatient = 13) were statistically significant (P < 0.001).
Rotavirus-related Inpatient Rate
The proportion of rotavirus-positive AGE hospitalizations among children younger than 5 
years accounted for 27.8% (142 of 511) of all AGE hospitalizations in Beijing Municipality 
and 45.0% (299 of 665) in Gansu Province (P < 0.001).
Population-based rates of rotavirus-related hospitalizations were 14.4 (95% CI, 13–16) per 
10,000 children younger than 5 years, corresponding to 1 in 694 children below 5 being 
hospitalized for rotavirus each year. The hospitalization rate associated with rotavirus AGE 
in children younger than 3 years was 24.0 (95% CI, 22–26) admissions per 10,000 children 
in our surveillance area.
Rotavirus AGE hospitalization rates were lower in Beijing Municipality (4.4 per 10,000, 
95% CI: 3.5–5.4 per 10,000) compared with Gansu Province (23.8 per 10,000, 95% CI: 22–
26 per 10,000) in children younger than 5 years. Infants <1 year old in Gansu Province had a 
significantly higher rotavirus AGE hospitalization rate (99.4 per 10,000, 95% CI: 90–109 
per 10,000) compared with Beijing Municipality (13.5 per 10,000, 95% CI: 10–18 per 
10,000). The rate in 1-year old (21.7 per 10,000) in Gansu Province was also significant 
higher than the rate in Beijing Municipality (8.8 per 10,000). But the hospitalization rates of 
2-year old (1.4 per 10,000), 3-year old (0 per 10,000) and 4-year old (0.5 per 10,000) 
children in Gansu Province were similar between Beijing Municipality (0.4 per 10,000; 0.3 
per 10,000 and 0.5 per 10,000), respectively.
Rotavirus-related Outpatient Visit Rate
The population-based rate of rotavirus AGE in the outpatient clinical setting was 149 (95% 
CI = 145–153) per 10,000 children younger than 5 years, corresponding to 1 in 67 children 
below 5 having an outpatient visit for rotavirus each year. In Beijing Municipality, the 
population-based outpatient visit rate was 147.5 (95% CI, 112–153) per 10,000 children. In 
Gansu Province, the outpatient visit rate was 150.4 (95% CI, 145–156) per 10,000 children. 
For infants <1-year old, the rotavirus outpatient rate in Beijing Municipality (379.7 per 
10,000) was lower than in Gansu Province (513.7 per 10,000) (P < 0.001). But the rates of 
rotavirus outpatient visits among 1-year olds (292.2 per 10,000), 2-year olds (57.1 per 
10,000), 3-year olds (27.0 per 10,000) and 4-year olds (22.0 per 10,1000) in Beijing 
Municipality were all higher than outpatient visit rates in Gansu Province (198.8 per 10,000, 
33.5 per 10,000, 11.3 per 10,000 and 11.6 per 10,000).
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Estimated Disease Burden and Economic Cost of Rotavirus-related AGE
Summed medical-related costs including direct and indirect medical costs per rotavirus AGE 
outpatient visit amounted to $144.90, derived from a sample of 199 rotavirus-positive AGE 
outpatient children (Table 3). The total cost per rotavirus AGE-hospitalized patient was 
$372.30, based on the cost of 323 patients with rotavirus-positive AGE in inpatient settings. 
If applied to the estimated number of patients with rotavirus-related AGE 3790 (95% CI: 
2488–3827) hospitalized patients and 29,101 (95% CI: 27,748–29,279) outpatient visits per 
year, the total cost of rotavirus in children younger than 5 years was $1.4 million (95% CI: 
$0.9–1.4 million) for hospitalizations and $4.2 million (95% CI: $4.0–4.2 million) for 
outpatient visits per year.
DISCUSSION
Our assessment of the epidemiology of rotavirus AGE in Chinese children clearly 
demonstrates the substantial disease burden from rotavirus and the potential for large 
benefits from vaccination in the future. Almost one-fourth (22%) of outpatient AGE visits 
and 37% of AGE hospitalizations were determined by laboratory confirmation to have been 
caused by rotavirus among children younger than 5 years from July 2012 to June 2013 in 
Beijing Municipality and Gansu Province. Population-based inpatient and outpatient visit 
rate estimates due to rotavirus gastroenteritis were similar to those among children younger 
than 5 years between 2000 and 2006 in the United States,10 and to those in Honjo city and 
surroundings in northern Japan (13/10,000).11 Our rotavirus rates are higher than the rates in 
2008 (4/10,000) and in 2009 (6/10,000) reported in the United States.10 Our rates were 
lower than Hangzhou of China (21/10,000) during 2007–2008 from a hospital-based 
study,12 and lower than Hong Kong of China (20/10,000) during 1987–1996.13 The 
inpatient rate (24/10,000) associated with rotavirus AGE in the subset of children younger 
than 3 years in our study was similar (22.5/10,000) to that found for children of this age in 
the United States during the last year before widespread use of rotavirus vaccines there, 
2006.9
The overall proportion (37%) of rotavirus-associated hospitalizations among children with 
AGE younger than 5 years decreased 21% and 24% compared with previously published 
rates during 2001–2003 and 2003–2007 in 11 Chinese sentinel sites, respectively, and this 
variability may be due to secular trends, differences in vaccination, study design factors, 
subject ages and hospital utilization practices.3,7 The rotavirus test-positive proportion 
(28.2%) of hospitalized children in Beijing Municipality decreased 20% compared with 36% 
during 2003–20073 and this was lower than the prevalence found in Morocco and Japan 
(44–56%)14,15 and was higher than that observed in Hong Kong.13
Our study found that medically attended rotavirus infections varied by surveillance location, 
particularly among the youngest subjects. The 0 to 2 and 3 to 5-month age groups in Beijing 
Municipality had a lower proportion of rotavirus positivity compared with those in Gansu 
Province. Seven percent (7%) of the enrolled subjects in Beijing Municipality were younger 
than 6 months, compared with 21% of those in Gansu Province. These youngest age groups 
are often considered to be protected through passive immunity via maternal antirotavirus 
antibodies; therefore, the relatively high rate of rotavirus hospitalizations and outpatient 
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visits among this age group observed in Gansu Province is striking and warrants further 
investigation. We found 21 infants 0–2 months old hospitalized with rotavirus infection in 
Gansu Province, and 16 (76%) had diagnosed co-morbidities. Among the 36 infants 3–5 
months old and hospitalized with rotavirus in Gansu Province, 12 (33.3%) had 
comorbidities. None of them had a reported history of receiving any rotavirus vaccinations. 
Rotavirus AGE may pose a sizeable threat for young infants suffering from other 
comorbidities, such as respiratory diseases and neonatal disorders.
Rotavirus-related AGE was characterized by fever, a long duration of diarrhea, vomiting and 
watery stool in our subjects, similar to other research.3,16-20 But nearly all (92.5%) rotavirus 
AGE patients were classified as having either moderate or severe classifications by Vesikari 
severity scale; higher than in hospitalized AGE patients in Greece (58.7%).17
Gansu Province and Beijing Municipality are situated in northern China. In our study, 
rotavirus infection occurred with similar seasonal patterns in Beijing Municipality and 
Gansu Province overall, with a first peak from October to December and a second peak from 
March to May. A double-peak pattern was also reported in Beijing Municipality during 
2001–2003, as well as in China’s Kunming City and Suzhou City.7 During 2001–2003 and 
2003–2007, southern China and northern China had no significant differences in peak 
seasonality.3,7 In the United States, the rotavirus epidemic peaked in the winter months 
during the period before widespread rotavirus vaccination,21 but now occurs for a delayed, 
truncated period.9 Further studies on rotavirus seasonality need to be conducted so as to 
understand geographic differences and other contributing factors.
We found that the rotavirus hospitalization rate and outpatient visit rate of patients <1-year 
old in Gansu Province was both higher than patients <1-year old in Beijing. The possible 
reasons involved in higher proportion of rotavirus positive in Gansu (45%, 195/436) than 
Beijing (25%, 71/280) in inpatient patients under 1 year old and higher severe cases’ 
percentage in Gansu (81%, 354/436) than Beijing (34%, 95/280). Our results also showed 
the higher visiting proportions in the outpatient settings in patients of 1-4-years old was 
found in Beijing than Gansu. This related to more proportions on patients >1-year old, mild 
patients and lower proportions of rotavirus positive in Beijing than Gansu.
Our study results showed that the average direct medical cost for outpatient visit and 
hospitalized patient was US $ 58.00 and was higher than the average cost (US $ 13.99) of 
rotavirus outpatient visits in 2006–2007 and the cost (US $ 13.51) in 2004 in China.22,23 
The direct medical cost (US $ 204.5) of hospitalization for rotavirus AGE is lower than 
previous funding of US $ 459.83 in 2006–2007, but is higher than the cost (US $108.96) in 
2004 in China.22,23 The total social cost (US $ 144.9) of outpatient visit per patient is higher 
than previous study (US $ 61.64), but the total health care cost of hospitalized patient per 
patient (US $ 372.3) is lower than previous study (US $ 684.15) in 2006–2007 in China.22 
Health care costs arising from outpatient visits are higher (300% increase) compared with 
these costs during 2006–2007 in China.
Our finding of G and P types circulating in Beijing and Gansu were predominated by 
G9P[8] was similar with Kenya (35%),24 but different from circulating strains of G3P8 
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(32.1%) before 2011 in China.25 G9 was also detected in Hebei province which is nearby 
Beijing from 2009.26 New rotavirus vaccines indicated for the prevention of rotavirus 
gastroenteritis caused by G1 and non-G1 types (G3, G4 and G9) in infants and children,27 
but have not been introduced to China. The Lanzhou Lamb rotavirus vaccine is currently 
approved for use in China, but is not part of the Expanded Program of Immunization and its 
cost is not covered by the national vaccination program. In our study, whereupon parents 
were asked for vaccination status during an interview, only a small proportion (2.5%) of 
children with diarrhea illness were reported to have received at least 1 vaccine dose. This is 
a lower proportion than observed in Guangzhou, China in 2009–2011, where 14.4% 
reportedly received at least 1 dose and 0.4% were vaccinated with a full course of 2 
doses.28,29 Increased use of effective rotavirus vaccines could dramatically decrease the 
disease burden due to rotavirus that we observed.
Extrapolating from our population-based findings to the Chinese population, we estimate 
110,000 (100,000–120,000) rotavirus hospitalizations and 1.2 million (1.1–1.2 million) 
outpatient visits occur per year in China in young children. The estimated social cost for 
rotavirus infection younger than 5 years is US $ 42 million per year for hospitalizations and 
US $ 168 million cost for outpatient visits per year in China. This disease burden baseline in 
children younger than 5 years during an era before widespread use of rotavirus vaccines 
could be helpful for assessing rotavirus vaccination policies.
Some limitations should be considered in the study. Including medical institutions in Beijing 
Municipality and Gansu Province provided differences in socioeconomic levels and health 
care access that may have been important to observed differences between these locations. 
Two areas belong to northern China through previous studies showed no significant 
different on seasonality. Another limitation is that we had low enrollment among outpatient 
AGE visits, due in part to the large number of children attending these outpatient settings, 
and this may have affected the representativeness of our outpatient estimates. We estimated 
the sample size with 20–30% positive rate and 10% lost visit rate after main visit for 
keeping the study samples for enrolling. We used the proportions of diarrhea cases in 
selected hospitals out of total reported diarrhea cases in surveillance areas of Gansu province 
for estimating capture rates, but it has limitation due to under-reporting. The daily and 
monthly statistics for all inpatient and outpatient visits for diarrhea or AGE were conducted 
but the detail information is limited for analysis. Although 1-year round active surveillance 
provides some seasonal pattern, but the epidemic strains changes and seasonality change 
cannot be captured.
China is the most populous nation in the world, with a large childhood population. Our study 
highlights that rotavirus infections bring large disease burden and economic social costs in 
children younger than 5 years. Further surveillance to document these burdens and to 
describe the potential benefits from rotavirus vaccines to reduce these burdens is needed in 
China.
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Geographic map of surveillance areas, China.
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(A) Rotavirus test-positive proportions in AGE patients younger than 5 years by month in 
Beijing. (B) Rotavirus test-positive proportions in AGE patients younger than 5 years by 
month in Gansu Province.
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(A) Rotavirus strains genotyping in children diarrhea patients in Beijing. (B) Rotavirus 
strains genotyping in children diarrhea patients in Gansu.
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TABLE 1
Rotavirus Laboratory Results by Patient Characteristics and by Surveillance Sites
Beijing Municipality (n = 1168) Gansu Province (n = 771)
RV neg. RV pos. RV pos. (%) RV neg. RV pos. RV pos. (%) P Value
Total 897 271 23.2 460 311 40.3 <0.001
Setting type
 Inpatient 343 138 28.7 297 245 45.2 <0.001
 Outpatient 554 133 19.4 163 66 28.8 0.003
Age group (mo)
 0–2 72 7 8.9 28 21 42.9 <0.001
 3–5 144 11 7.1 104 45 30.2 <0.001
 6–11 360 110 23.4 214 172 44.6 <0.001
 12–17 138 92 40.0 69 51 42.5 0.652
 18–23 81 23 22.1 29 13 31.0 0.262
 24–35 48 14 25.8 9 6 27.3 0.924
 36–47 33 7 17.5 4 1 20.0 1.000
 48–59 21 7 25.0 3 2 40.0 0.597
Gender
 Male 557 161 22.4 291 199 40.6 <0.001
 Female 340 110 24.4 169 112 39.9 <0.001
Registration type
 Urban 625 164 20.8 147 99 40.2 <0.001
 Rural 272 107 28.2 313 212 40.4 <0.001
Insurance
 Yes 160 62 27.9 172 105 37.9 0.019
 No 737 209 22.1 288 206 41.7 <0.001
Rotavirus vaccination
 Yes 13 5 27.8 21 9 30.0 0.870
 No 884 266 23.1 439 302 40.8 <0.001
RV indicates Rotavirus.
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TABLE 2







(n = 1357) P Value
Vesikari scale score <0.001
 <11 44 (7.6) 150 11.1
 11–14 168 (28.9) 659 48.6
 ≥15 370 (63.6) 548 40.4
Diarrhea duration (days) 0.003
 <4 days 359 (61.7) 845 (62.3)
 4–5 days 105 (18.0) 173 (12.7)
 6 days and above 113 (19.4) 326 (24.0)
Maximum diarrhea episodes <0.001
 <4 95 (16.3) 395 (29.1)
 4–5 167 (28.7) 427 (31.5)
 ≥6 320 (55.0) 527 (38.8)
Maximum body temperature <0.001
 <38.5°C 261 (44.8) 539 39.7
 38.5–38.9°C 65 (11.2) 68 5.0
 ≥39°C 79 (13.6) 75 5.5
Maximum vomiting episodes 0.028
 1 66 (11.3) 114 8.4
 2–4 171 (29.4) 207 15.3
 5 and above 39 (6.7) 33 2.4
Behavioral Status <0.001
 Normal behavior 526 (90.4) 1316 97.0
 Restless/Irritable 23 (4.0) 19 1.4
 Lethargic 32 (5.5) 21 1.5
Dehydration 0.912
 Sunken eyes 176 (30.2) 234 17.2
 Dry mouth/tongue 231 (39.7) 323 23.8
 Retraction of skin ≥2 seconds 20 (3.4) 29 2.1
RV indicates Rotavirus.
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TABLE 3








Nonmedical Cost Indirect Cost Total Cost






Beijing Outpatient 55.4 14.3 74.6 144.3 7929 (7799–8153) 1.1 (1.1–1.2)
Inpatient 78.1 28.4 101.6 208.1 241 (177–273) 0.1 (0.08–0.1)
Gansu Outpatient 60.5 23.2 61.6 145.3 21172 (20405–21953) 3.1 (3.0–3.2)
Inpatient 330.9 50.7 154.7 536.3 3549 (3096–3659) 1.9 (1.7–2.0)
Beijing and
Gansu
Outpatient 58.0 18.8 68.1 144.9 29101 (27748–29279) 4.2 (4.0–4.2)
Inpatient 204.5 39.6 128.2 372.3 3790 (2488–3827) 1.4 (0.9–1.4)
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